Sunshine Biopharma Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$6.30next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 15 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Generic Drug Portfolio Count Quarterly60
Quarterly Revenue Quarterly8.1M
Gross Margin Quarterly2,700.0%Target: 35%
Watch Items
- Nasdaq Minimum Bid Price ComplianceTrigger: Stock price falling below $1.00 for 30 consecutive business daysAction: Implement reverse stock split or other capital restructuring measures to maintain listing.
- Cash Runway and Burn RateTrigger: Cash reserves falling below $5.0 million or monthly burn exceeding $1.0 millionAction: Initiate cost-reduction measures or seek non-dilutive funding/equity financing.
- Proprietary Pipeline Milestones (K1.1 mRNA and PLpro inhibitor)Trigger: Delays in preclinical animal testing or IND-enabling studiesAction: Reallocate R&D resources or seek strategic research partnerships to accelerate development.
Research as of 20 Jun 2026